Gapping down
In reaction to disappointing earnings/guidance: AKAM -18.6%, TWTR -10.6%, GNMK -9.6%, KKR -7.9%, (announces $500 mln buyback; sets quarterly distribution at $0.16/unit), BGFV -5.4%, LYG -4.4%, BKFS -3.8%, SMED -3%, BBOX -2.6%, STO -2.6%, HSY -2.6%, RUBI -2.5%, CMC -2.3%, KTCC -1.8%, VRSK -1.7%, (is exploring strategic alternatives for its healthcare data analytics business, Verisk Health ), WBA -1.7%, SNCR -1.3%, ESRX -1.2%, CARB -1.2%, GILD -1.1%, GRMN -1.1%, LMAT -1%, SKT -0.8%
M&A news: RAD -8.1% (after 40%+ move higher yesterday on WSJ report that Walgreens Boot Alliance is near a deal to acquire Rite Aid; WBA/RAD confirmed news after the close), WBA -1.8% (jumped 6% yesterday on WSJ report that Walgreens Boot Alliance is near a deal to acquire Rite Aid; WBA/RAD confirmed news after the close)
Other news: MCUR -66.7% ( Announces Results for Phase III Clinical Trial of CureXcell(R) in Diabetic Foot Ulcers; Trial did did not meet its primary endpoint, did not meet the secondary endpoints), ICPT -11% (announces results of Phase 2 Trial of OCA in NASH patients in Japan), FRED -3.7% (late boost following analyst comments suggesting potential takeover), HCLP -3.1% (cont weakness), BA -1.6% (loss of Long Range Strike-Bomber contract to Northrop Grumman), LMT -0.7% (loss of Long Range Strike-Bomber contract to Northrop Grumman)
Analyst comments: YELP -3.9% (initiated with a Sell at ROTH Capital; tgt $17.50), CMI -2% (downgraded to Underweight from Equal-Weight at Morgan Stanley), MRVL -2% (downgraded to Sell from Neutral at Citigroup), HIG -0.5% (downgraded to Neutral from Overweight at Atlantic Equities
)
In reaction to disappointing earnings/guidance: AKAM -18.6%, TWTR -10.6%, GNMK -9.6%, KKR -7.9%, (announces $500 mln buyback; sets quarterly distribution at $0.16/unit), BGFV -5.4%, LYG -4.4%, BKFS -3.8%, SMED -3%, BBOX -2.6%, STO -2.6%, HSY -2.6%, RUBI -2.5%, CMC -2.3%, KTCC -1.8%, VRSK -1.7%, (is exploring strategic alternatives for its healthcare data analytics business, Verisk Health ), WBA -1.7%, SNCR -1.3%, ESRX -1.2%, CARB -1.2%, GILD -1.1%, GRMN -1.1%, LMAT -1%, SKT -0.8%
M&A news: RAD -8.1% (after 40%+ move higher yesterday on WSJ report that Walgreens Boot Alliance is near a deal to acquire Rite Aid; WBA/RAD confirmed news after the close), WBA -1.8% (jumped 6% yesterday on WSJ report that Walgreens Boot Alliance is near a deal to acquire Rite Aid; WBA/RAD confirmed news after the close)
Other news: MCUR -66.7% ( Announces Results for Phase III Clinical Trial of CureXcell(R) in Diabetic Foot Ulcers; Trial did did not meet its primary endpoint, did not meet the secondary endpoints), ICPT -11% (announces results of Phase 2 Trial of OCA in NASH patients in Japan), FRED -3.7% (late boost following analyst comments suggesting potential takeover), HCLP -3.1% (cont weakness), BA -1.6% (loss of Long Range Strike-Bomber contract to Northrop Grumman), LMT -0.7% (loss of Long Range Strike-Bomber contract to Northrop Grumman)
Analyst comments: YELP -3.9% (initiated with a Sell at ROTH Capital; tgt $17.50), CMI -2% (downgraded to Underweight from Equal-Weight at Morgan Stanley), MRVL -2% (downgraded to Sell from Neutral at Citigroup), HIG -0.5% (downgraded to Neutral from Overweight at Atlantic Equities
)